| The clinical pharmacology of cladribine tablets for the treatment of relapsing multiple sclerosis R Hermann, MO Karlsson, AM Novakovic, N Terranova, M Fluck, ... Clinical Pharmacokinetics 58, 283-297, 2019 | 63 | 2019 |
| Application of machine learning in translational medicine: current status and future opportunities N Terranova, K Venkatakrishnan, LJ Benincosa The AAPS Journal 23 (4), 74, 2021 | 50 | 2021 |
| Pharmacometrics Markup Language (PharmML): opening new perspectives for model exchange in drug development MJ Swat, S Moodie, SM Wimalaratne, NR Kristensen, M Lavielle, A Mari, ... CPT: pharmacometrics & systems pharmacology 4 (6), 316-319, 2015 | 41 | 2015 |
| A predictive pharmacokinetic–pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination N Terranova, M Germani, F Del Bene, P Magni Cancer chemotherapy and pharmacology 72, 471-482, 2013 | 37 | 2013 |
| Mouse embryonic stem cells that survive γ‐rays exposure maintain pluripotent differentiation potential and genome stability P Rebuzzini, D Pignalosa, G Mazzini, R Di Liberto, A Coppola, ... Journal of cellular physiology 227 (3), 1242-1249, 2012 | 33 | 2012 |
| Fast screening of covariates in population models empowered by machine learning E Sibieude, A Khandelwal, JS Hesthaven, P Girard, N Terranova Journal of Pharmacokinetics and Pharmacodynamics 48 (4), 597-609, 2021 | 31 | 2021 |
| White paper: landscape on technical and conceptual requirements and competence framework in drug/disease modeling and simulation G Vlasakakis, E Comets, A Keunecke, I Gueorguieva, P Magni, ... CPT: pharmacometrics & systems pharmacology 2 (5), 1-8, 2013 | 21 | 2013 |
| Population pharmacokinetic model selection assisted by machine learning E Sibieude, A Khandelwal, P Girard, JS Hesthaven, N Terranova Journal of Pharmacokinetics and Pharmacodynamics 49 (2), 257-270, 2022 | 19 | 2022 |
| Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types N Terranova, M Jansen, M Falk, BS Hendriks Cancer Chemotherapy and Pharmacology 87, 185-196, 2021 | 18 | 2021 |
| Machine learning analysis of individual tumor lesions in four metastatic colorectal cancer clinical studies: linking tumor heterogeneity to overall survival D Vera-Yunca, P Girard, ZP Parra-Guillen, A Munafo, IF Trocóniz, ... The AAPS journal 22, 1-12, 2020 | 18 | 2020 |
| Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumab N Terranova, J French, H Dai, M Wiens, A Khandelwal, A Ruiz‐Garcia, ... CPT: pharmacometrics & systems pharmacology 11 (3), 333-347, 2022 | 15 | 2022 |
| Assessing similarity among individual tumor size lesion dynamics: the CICIL methodology N Terranova, P Girard, K Ioannou, U Klinkhardt, A Munafo CPT: pharmacometrics & systems pharmacology 7 (4), 228-236, 2018 | 14 | 2018 |
| Predicting disease activity in patients with multiple sclerosis: An explainable machine‐learning approach in the Mavenclad trials S Basu, A Munafo, AF Ben‐Amor, S Roy, P Girard, N Terranova CPT: Pharmacometrics & Systems Pharmacology 11 (7), 843-853, 2022 | 12 | 2022 |
| Model description language (MDL): a standard for modeling and simulation MK Smith, SL Moodie, R Bizzotto, E Blaudez, E Borella, L Carrara, ... CPT: pharmacometrics & systems pharmacology 6 (10), 647, 2017 | 12 | 2017 |
| Resistance development: a major piece in the jigsaw puzzle of tumor size modeling N Terranova, P Girard, U Klinkhardt, A Munafo CPT: Pharmacometrics & Systems Pharmacology 4 (6), 320-323, 2015 | 12 | 2015 |
| Effects of postponing treatment in the second year of cladribine administration: Clinical trial simulation analysis of absolute lymphocyte counts and relapse rate in patients … N Terranova, C Hicking, F Dangond, A Munafo Clinical pharmacokinetics 58, 325-333, 2019 | 11 | 2019 |
| Modeling tumor growth inhibition and toxicity outcome after administration of anticancer agents in xenograft mice: a dynamic energy budget (DEB) approach N Terranova, EM Tosca, E Borella, E Pesenti, M Rocchetti, P Magni Journal of theoretical biology 450, 1-14, 2018 | 11 | 2018 |
| A minimal model of tumor growth inhibition in combination regimens under the hypothesis of no interaction between drugs P Magni, N Terranova, F Del Bene, M Germani, G De Nicolao IEEE transactions on biomedical engineering 59 (8), 2161-2170, 2012 | 10 | 2012 |
| TGI-Simulator: a visual tool to support the preclinical phase of the drug discovery process by assessing in silico the effect of an anticancer drug N Terranova, P Magni Computer methods and programs in biomedicine 105 (2), 162-174, 2012 | 10 | 2012 |
| Artificial intelligence for quantitative modeling in drug discovery and development: an innovation and quality consortium perspective on use cases and best practices N Terranova, D Renard, MH Shahin, S Menon, Y Cao, CECA Hop, ... Clinical Pharmacology & Therapeutics 115 (4), 658-672, 2024 | 9 | 2024 |
